Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO – Get Free Report)’s stock price passed below its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $0.25 and traded as low as $0.2310. Northwest Biotherapeutics shares last traded at $0.2355, with a volume of 1,462,260 shares traded.
Northwest Biotherapeutics Stock Up 0.6%
The business’s fifty day moving average is $0.26 and its 200-day moving average is $0.25. The company has a market cap of $376.22 million, a PE ratio of -0.01 and a beta of -0.86.
Northwest Biotherapeutics Company Profile
Northwest Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of personalized dendritic cell immunotherapies for the treatment of cancer. The company’s proprietary platform harnesses patient-derived dendritic cells to present tumor-specific antigens and stimulate a targeted immune response. By tailoring each vaccine to the individual patient’s tumor profile, the approach aims to improve outcomes and reduce off-target toxicity associated with conventional therapies.
The company’s lead candidate, DCVax®-L, is designed for patients with newly diagnosed or recurrent glioblastoma multiforme (GBM) and has advanced through a global Phase III clinical trial.
Featured Stories
- Five stocks we like better than Northwest Biotherapeutics
- REVEALED: Something Big Happening Behind White House Doors
- ALERT: Drop these 5 stocks before the market opens tomorrow!
- Elon Musk: This Could Turn $100 into $100,000
- Read this or regret it forever
- The Next Commodity Crunch (bigger than oil?)
Receive News & Ratings for Northwest Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Northwest Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
